CN103941001B - 猪副嗜血杆菌快速检测试纸条 - Google Patents
猪副嗜血杆菌快速检测试纸条 Download PDFInfo
- Publication number
- CN103941001B CN103941001B CN201310083786.3A CN201310083786A CN103941001B CN 103941001 B CN103941001 B CN 103941001B CN 201310083786 A CN201310083786 A CN 201310083786A CN 103941001 B CN103941001 B CN 103941001B
- Authority
- CN
- China
- Prior art keywords
- haemophilus parasuis
- trace
- fibrage
- parasuis infection
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 74
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 73
- 241000606807 Glaesserella parasuis Species 0.000 title claims abstract description 51
- 238000001514 detection method Methods 0.000 title claims abstract description 27
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000010931 gold Substances 0.000 claims abstract description 30
- 229910052737 gold Inorganic materials 0.000 claims abstract description 30
- 229920002678 cellulose Polymers 0.000 claims abstract description 23
- 239000001913 cellulose Substances 0.000 claims abstract description 23
- 241000283973 Oryctolagus cuniculus Species 0.000 claims abstract description 11
- 241001494479 Pecora Species 0.000 claims abstract description 11
- 239000002250 absorbent Substances 0.000 claims abstract description 10
- 230000002745 absorbent Effects 0.000 claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002372 labelling Methods 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 24
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 18
- 239000011491 glass wool Substances 0.000 claims description 14
- 238000001179 sorption measurement Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 238000002965 ELISA Methods 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000000020 Nitrocellulose Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000003550 marker Substances 0.000 claims description 6
- 229920001220 nitrocellulos Polymers 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 4
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 210000004408 hybridoma Anatomy 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 4
- 238000002649 immunization Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000123 paper Substances 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 239000004033 plastic Substances 0.000 claims description 4
- 238000001556 precipitation Methods 0.000 claims description 4
- 210000004988 splenocyte Anatomy 0.000 claims description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 241000446313 Lamella Species 0.000 claims description 2
- 239000004677 Nylon Substances 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 210000005252 bulbus oculi Anatomy 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 229920001778 nylon Polymers 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 7
- 239000011888 foil Substances 0.000 abstract description 3
- 238000007689 inspection Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 238000006243 chemical reaction Methods 0.000 abstract 2
- 238000012856 packing Methods 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 15
- 241000282898 Sus scrofa Species 0.000 description 13
- 239000007788 liquid Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 208000008423 pleurisy Diseases 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 244000208060 Lawsonia inermis Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010036141 Polyserositis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241001135557 Enteric coronavirus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000725681 Swine influenza virus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- -1 propylene glucosan Chemical compound 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nanotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明涉及一种猪副嗜血杆菌诊断试剂显示的器具,特别是涉及一种猪副嗜血杆菌快速诊断试纸条,试纸条含有支撑层、反应试剂载体吸附层,支撑层为不吸水薄片条,反应试剂载体吸附层粘贴于支撑层上,从样品测试端依次为纤维层,猪副嗜血杆菌金标单抗或多抗纤维层,纤维素膜层,手柄端为吸水材料层;分别用猪副嗜血杆菌配对单抗或多抗或单抗溶液在纤维层上印制检测印迹“<b>|</b>”、?“<b>/</b>”?或“<b>\</b>”,分别用羊(兔)抗小鼠或猪IgG的多抗或用SPA溶液在纤维素膜层上印制对照印迹“<b>|</b>”、?“<b>/</b>”?或“<b>\</b>”。该检测试纸条,特异性强,敏感性高,检测结果显示形象、直观、准确,无需仪器设备,无需专业检测人员,费用低,操作简便、快速,可大大降低劳动强度,缩短检测时间,能在饲养场,肉类加工厂,出入境检验检疫局等场所进行现场检测,易于推广应用。
Description
一、技术领域
本发明是一种涉及猪副嗜血杆菌的检测试剂显示器具,特别是涉及一种可检测猪副嗜血杆菌的检测试纸条。
二、技术背景
猪副嗜血杆菌病(haemophilus parasuis)又称格氏病、纤维素性浆膜炎和关节炎,是由猪副嗜血杆菌引起猪的多发性浆膜炎和关节炎的统称⋯。猪副嗜血杆菌可以影响从2周龄到4月龄的青年猪,主要在断奶后和保育阶段发病,通常见于5-8周龄的猪,发病率一般在l0%~l5%,严重时死亡率可达50%。主要临床症状表现为咳嗽、呼吸困难、消瘦、跛行和被毛粗乱;主要剖检病变表现为纤维素性胸膜炎、心包炎、腹膜炎、关节炎和脑膜炎等。此外,猪副嗜血杆菌还可引起败血症,并且在急性感染后可能留下后遗症,即母猪流产、公猪慢性跛行。
猪副嗜血杆菌只感染猪,有很强的宿主特异性。该病主要通过空气、猪与猪之间的接触或通过污染排泄物进行传播。病猪和带菌猪是该病主要传染源。有些病原体可促进猪副嗜血杆菌的感染,如猪圆环病毒、猪蓝耳病病毒、猪流感病毒、伪狂犬病毒、呼吸道冠状病毒、肺炎支原体等都可促进或加重猪副嗜血杆菌的感染,而猪副嗜血杆菌的存在也会加剧原发病的临床表现。该病常与PRRS并发,在猪群中存在PRRS感染时,猪副嗜血杆菌的分离率会增加,由猪副嗜血杆菌导致的死亡率也大幅度增加。
主要剖检病变表现为,慢性型病例最特殊的病理变化是纤维性化脓性支气管肺炎,兼有纤维性胸膜炎。病灶往往出现在肺脏背部,呈圆形,有明显的界限。肺部早期组织学病变包括坏死、出血,嗜中性白细胞浸润,巨嗜细胞和血小板激活,血管内血栓形成;后期则主要以巨嗜细胞浸润为特征。急性型病例的特征性病变是浆液性纤维蛋白性多发性浆膜炎和多发性关节炎。主要表现为胸膜炎、腹膜炎、脑膜炎、心包炎、关节炎。通常在肺的横隔膜叶较易出现病灶,全身淋巴结肿大,暗红色,切面呈大理石花纹;肾、十二指肠均有出血点,回盲口附近有轮层扣状溃疡;脾出血性梗死。
对猪副嗜血杆菌的检测主要通过细菌分离鉴定、琼脂扩散试验、补体结合试验,对该病的诊断主要通过细菌分离鉴定、间接血凝抑制试验、琼脂扩散试验、补体结合试验 。目前,采用猪副嗜血杆菌全菌体作为包被抗原,建立了检测猪副嗜血杆菌抗体的间接ELISA方法。聚合酶链式反应(PCR)技术,该方法具有高灵敏度、高特异性等优点,PCR检测方法已被广泛运用于猪副嗜血杆菌的鉴定和流行病学调查。
上述检测方法需要专业人员在实验室操作,操作繁琐,检测费时费力;而且需要昂贵的仪器设备,如PCR仪、酶标仪等,对非专业人员而言,上述检测方法很难完成。虽然上述方法特异敏感,但无法实现现场快速检测或诊断。本发明,研究一种简便快速、实时在线检测试纸,对控制和消灭此疾病意义重大。
三、发明内容
本发明的目的是为了克服现有技术中检测猪病病原存在的缺点,提供一种特异、敏感、简便快速的猪副嗜血杆菌检测方法,研制出检测猪副嗜血杆菌的检测试纸条。
本发明的技术方案是:提供一种猪副嗜血杆菌的检测试纸条,该试纸条含有支撑层和吸附层,支撑层为不吸水的薄片层,吸附层附着在支撑层上,吸附层从测试端依次为样品吸附纤维层、金标抗体纤维层、纤维素膜层和手柄端的吸水材料层,在纤维素膜层上设有检测印迹和对照印迹;金标抗体纤维层吸附有纳米级金颗粒标记的抗猪副嗜血杆菌的单克隆抗体,检测印迹用抗猪副嗜血杆菌的配对单抗印制,对照印迹用羊或兔抗小鼠IgG的多克隆抗体;或金标抗体纤维层吸附有纳米级金颗粒标记的抗猪副嗜血杆菌的多克隆抗体,检测印迹用抗猪副嗜血杆菌的单抗制备,对照印迹用金黄色葡萄球菌A蛋白(SPA)或抗猪IgG多抗制备。
检测印迹用抗猪副嗜血杆菌的配对单抗制备即用猪副嗜血杆菌的配对单抗溶液制备;检测印迹用抗猪副嗜血杆菌的多克隆抗体制备即为用猪副嗜血杆菌的多克隆抗体制备。
支撑层用不吸水的硬质塑胶片条或硬纸条制成;测试端样品吸附纤维层用玻璃棉制成;金标抗体纤维层用玻璃棉和金标抗体制成,金标抗体可以是单抗或多克隆抗体。
纤维素膜层用硝酸纤维素膜、或纯纤维素膜、或羧化纤维素膜、或聚偏二氟乙烯PVDF纤维素膜制成。
吸水材料层用吸水纸制成。
检测印迹和对照印迹为直线式、或斜线式,纤维素膜层上含有一条检测印迹和一条对照印迹,检测印迹和对照印迹的排列形式为“||”、“/ /”、“\\”中的任一种。
试纸条吸附层上面含有一层保护层,保护层附着在吸附层上,在测试端样品吸附纤维层、金标抗体纤维层及吸水材料层上覆盖有保护膜,在测试端样品吸附纤维层与金标抗体纤维层交界处对应的保护膜上印制有样品标记线,该标记线偏向测试端样品吸附纤维层一侧处约0.5cm处。
根据需要,选择上述金标抗体纤维层、检测印迹和对照印迹排列形式中一种形式。
本发明的积极有益效果:
1. 检测特异性强、敏感性高:本发明检测试纸条以纳米级金颗粒标记高亲和力特异性单克隆抗体或特异性多克隆抗体为基础而制成,金标抗体中金颗粒与抗体分子之间无共价键形成,二者通过异性电荷间的范德华力相结合,金颗粒不影响单克隆抗体或多克隆抗体的特异性和结合力,并且具有较高的标记率。本发明检测试纸条具有较高的特异性和敏感性,可检测到纳克级病原体蛋白。
2. 操作简便、快速:使用本发明试纸条检测时无需附加任何其它仪器和试剂,只需将其测试端插入待检的样品液中30秒左右,然后在1-5分钟内即可判定检测结果。
3. 检测结果直观、准确:本发明试纸条以是否显示棕红色的检测线和对照线作为判定阳性和阴性结果的依据,即只在纤维素膜的对照线印记处显示一条棕红色对照线C,而在检测线印记处无棕红色条带显示,表示被检测的猪副嗜血杆菌为阴性结果;在纤维素膜的对照线印记处显示一条棕红色对照线C,在检测印迹处显示一条棕红色条带T,则表示被检测的猪副嗜血杆菌为阳性结果。无论阳性结果或阴性结果对照线C均应显示,当对照线C不显示时,说明试纸条失效。
4.检测费用降低:使用本发明检测试纸条,不需其它仪器及试剂,节省了仪器、设备和附加试剂费用;非专业人员也可随时实时在线检测,无需支付专家诊断检查费及其相关费用,可极大的降低检测成本的投入,降低检测费用。
5.使用范围广:本发明检测试纸条操作简单,即“傻瓜式”操作,而且携带方便、易保存,可满足不同单位和不同层次人员的需要,包括专业化验、海关检疫、卫生防疫、质量监测、畜产品加工、集约化养殖到个体养殖等,具有广阔的市场前景和社会效益。
四、附图说明:
图 1 一种猪副嗜血杆菌的检测试纸条的侧视结构示意图
图 2 一种猪副嗜血杆菌的检测试纸条的俯视结构示意图
五、具体实施方式:
以下实施例仅为了进一步说明本发明,并不限制本发明的内容。猪副嗜血杆菌检测试纸条的制备,需要制备抗猪副嗜血杆菌的单克隆抗体和多克隆抗体,用于制备检测印迹和金标抗体纤维层;同时需要制备羊或兔抗鼠IgG抗体,羊或兔抗猪IgG抗体,用于制备对照印迹。
1.羊(兔)抗鼠或抗猪IgG抗体的制备:
以饱和硫酸铵法提取小鼠或猪血清中的IgG,取1份血清加2份PBS液(pH 7.2)混匀,加等体积饱和硫酸铵液混匀,置4℃冰箱内2h,在4℃、10000r/min离心15min,弃上清液;以适量PBS液(pH7.2)溶解沉淀,加饱和硫酸铵液至其最终浓度为33%,置4℃冰箱内2h,在4℃、10000r/min条件下离心15min,弃上清液,以少量PBS液(pH7.2)溶解沉淀,置4℃冰箱内用PBS液(pH7.2)过夜透析,换液2~3次,在4℃、10000r/min条件下离心15min,收集上清液,以紫外分光光度计测定其蛋白浓度。以50μg~100μg(IgG)/kg体重经皮下或肌肉注射抗体阴性健康羊或家兔3~4次,末次免疫20天后,静脉采血,以ELISA测定其血清抗体效价在1:2000以上,心脏采血或颈动脉放血,收集其高免血清,以饱和硫酸铵法提取羊(兔)抗小鼠或猪的IgG(其提取方法与上述提取小鼠血清IgG相同,不再重述),用于制备本发明试纸条的对照印迹。
2. 猪副嗜血杆菌单克隆抗体(Mi)的制备:
每只用50μg~100μg 猪副嗜血杆菌抗原免疫Balb/c系小鼠三次,每次间隔15~30d;第三次加强免疫后3~4d,将免疫小鼠眼球放血,拉颈致死,用75%酒精浸泡5~10min,无菌取其脾脏,剪碎并经100目尼龙网过滤,1000r/min离心10min,收集脾细胞;将1×108个脾细胞与2~5×107个NS0骨髓瘤细胞混合,1000r/min离心10min弃上清,将含有沉淀细胞的离心管置于37℃的水中,并缓缓加入0.7~1ml 40%~50% PEG4000(pH 8.5~9.0)作用1min,然后缓慢加入无血清1640培养基15ml,以终止PEG的作用,37℃水浴5~10min,1000r/min离心10min弃上清,将细胞沉淀重悬于HAT选择培养基中,并加入
96孔培养板(100µl~200µl/孔),置于37℃ 5% CO2培养箱中培养。培养7~10d后,以5μg~10μg/ml的纯化的病原体特异抗原包被96孔酶标板,以酶联免疫吸附试验(ELISA)检测杂交瘤的培养上清,挑取强阳性细胞克隆(OD450≥0.5),进行连续三次的有限稀释法克隆化,获得阳性杂交瘤细胞株,其染色体数为92~98,其分泌的单克隆抗体,能够特异识别猪副嗜血杆菌,而不与其它毒素发生交叉反应,亲和力常数达109~10,轻链亚型为к或λ,重链亚型为IgG1、IgG2a、IgG2b、IgG3;获得的配对单克隆抗体,用于制金标单抗体玻璃棉或检测印迹。
3.金标单抗玻璃棉的制备:
利用柠檬酸钠还原法制备纳米级金颗粒:即在50~100ml沸腾的0.01~0.05%氯金酸水溶液中加入2~4ml的0.5~2%柠檬酸三钠溶液,获得直径15nm左右的纳米级金颗粒。以0.1mol/L的K2CO3调金颗粒溶液的pH至8.5~9.5,以1:1000~1300的标记比将待标记的单克隆抗体加入pH8.5~9.5的金溶胶中,标记10min后,加20% PEG10000至最终浓度为0.05%,4℃、1500~3000r/min离心20min,除去未结合的金颗粒颗粒,4℃、15000r/min离心1h,弃上清,获金标抗体混合物后,用丙烯葡聚糖S-400柱层析,分离纯化金标抗体,获得的金标抗体。将1:100~500稀释的金标抗体,吸附于精制玻璃棉中,4℃低温真空干燥,制备金标单克隆抗体玻璃棉。
4. 猪副嗜血杆菌多克隆抗体(Ci)的制备:
猪副嗜血杆菌多克隆抗体(Ci)的制备。采用猪副嗜血杆菌抗原多次免疫接种抗体阴性健康猪。末次免疫20天后静脉采血,以ELISA测定其血清抗体效价在1:2000以上,心脏采血或颈动脉放血,收集其高免血清,以饱和硫酸铵法提取血清中IgG抗体(方法与小鼠血清IgG的提取相同,不再重述)。
金标多抗和金标多抗玻璃棉的制备,与金标单抗玻璃棉的制备方法相同,不再重述。详见具体实施方式中的内容3。
5. 本发明检测试纸条检测原理
当本发明检测试纸条测试端插入待检样品溶液后,待检溶液通过虹吸带动待检猪副嗜血杆菌进入金标抗体纤维层,并与其中的金标抗体(Mi或Ci)一起沿硝酸纤维素膜向手柄端扩散,最终渗入手柄端吸水材料层,扩散过程中金标抗体能够与相应的待检猪副嗜血杆菌结合,结合金标抗体的猪副嗜血杆菌能够被纤维素膜上检测印迹的配对单抗或多抗拦截,当样品液中含有被检猪副嗜血杆菌时,则出现一条棕红色的检测线;羊或兔抗鼠或抗猪IgG则可与相应的金标单抗或多抗结合,出现1条棕红色对照线。当待检样品液中不含猪副嗜血杆菌时,试纸条只显示出一条棕红色对照线;当纤维素膜上没有对照线显示时,则表明试纸条已失效。
6. 本发明检测试纸条的检测操作方法
(1)检测样品的处理:取病猪病变组织, 1:1~5 加入生理盐水并用剪刀剪碎,浸出液为待检样品,病猪全血或血清加入生理盐水1:1~5稀释后为待检样品。
(2)检测操作:将本发明检测试纸条样品端插入待检样品液中,插入深度不超过标记线9,约30秒后取出试纸条,水平放置约1~5分钟,同时观察结果。
(3)结果判定:如果在检测试纸条纤维素膜上只显示出一条棕红色对照线C,表示检测结果为阴性,说明在被检样品中不含猪副嗜血杆菌;如果检测试纸条上的纤维素膜出现对照线C,检测印迹处出现一条检测线,表示检测结果为阳性,即在待检样品中含有猪副嗜血杆菌;如果纤维素膜上没有对照线C显示,则表明试纸条已失效。
实施例一:猪副嗜血杆菌的检测试纸条
参见图1和图2,图中1为支撑层,用硬质塑胶薄片条制成,2为测试端的样品吸附纤维层,用玻璃棉制成,3为金标抗体纤维层,吸附有纳米级金颗粒标记的抗猪副嗜血杆菌的单克隆抗体的玻璃棉,根据上述具体实施方式3中所述的制备方法制备其金标单抗玻璃棉,4为纤维素膜层,采用硝酸纤维素膜制成,5为吸水材料层,用吸水纸制成,将编号2、3、4、5各层从左端测试端至右粘贴在硬质塑胶薄片条1上,彼此之间交界处互相交叉重叠。在硝酸纤维素膜层4上,6为用抗猪副嗜血杆菌的配对单抗溶液印制的检测印迹T,7为用羊或兔抗鼠IgG溶液印制的对照印迹C,检测印迹和对照印迹为直线式、或斜线式,两种印迹带排列形成的组合形式为“||”、 “/ /”、“\\”中的任一种。8-1为覆盖在测试端样品吸附纤维层2和金标抗体纤维层3上面的白色保护膜,在2和3交界处对应保护膜8-1位置上偏向于样品吸附纤维层2一侧0.5cm处印有标记线9,9的右端印有箭头及max字样,吸水材料层5(手柄端)上覆盖有其它颜色(如黄色)保护膜8-2。
待测样品溶液的制备及检测操作步骤,与具体实施方式6中的检测操作方法相同,不再重述。
实施例二:猪副嗜血杆菌的检测试纸条,与实施例一基本相同,不同之处在于:
金标抗体纤维层3用吸附有金颗粒标记的抗猪副嗜血杆菌的多克隆抗体的玻璃棉制成,根据上述具体实施方式3中所述的制备方法制备其金标多克隆抗体玻璃棉;在硝酸纤维素膜层4上,6为用抗猪副嗜血杆菌的单抗溶液印制的检测印迹T,7为用羊或兔抗猪IgG溶液印制对照印迹C,两种印迹带排列形成的组合形式为“||”、 “/ /”、“\\”中的任一种。其它包括检测样品制备、操作方法和结果判定等均与具体实施方式6中的操作方法相同,不再重述。
Claims (7)
1.一种检测猪副嗜血杆菌的检测试纸条,该试纸条含有支撑层和吸附层,支撑层为不吸水的薄片层,吸附层附着在支撑层上,吸附层从测试端依次为样品吸附纤维层、金标抗体纤维层、纤维素膜层和手柄端的吸水材料层,在纤维素膜层上制备有检测印迹和对照印迹,其特征是金标抗体纤维层吸附有纳米级金颗粒标记的抗猪副嗜血杆菌的单克隆抗体,检测印迹用抗猪副嗜血杆菌的配对单抗或多克隆抗体印制,对照印迹用羊或兔抗小鼠IgG的多克隆抗体或金黄色葡萄球菌A蛋白印制;或金标抗体纤维层吸附有纳米级金颗粒标记的抗猪副嗜血杆菌的多克隆抗体,检测印迹用抗猪副嗜血杆菌的单抗制备,对照印迹用金黄色葡萄球菌A蛋白或抗猪IgG多抗制备;
其中,抗猪副嗜血杆菌单克隆抗体制备方法如下:
用50μg~100μg猪副嗜血杆菌抗原免疫Balb/c系小鼠三次,每次间隔15~30d;第三次加强免疫后3~4d,将免疫小鼠眼球放血,拉颈致死,用75%酒精浸泡5~10min,无菌条件下取其脾脏,剪碎并经100目尼龙网过滤,1000r/min离心10min,收集脾细胞;将1×108个脾细胞与2~5×107个NS0骨髓瘤细胞混合,1000r/min离心10min弃上清,将含有沉淀细胞的离心管置于37℃的水中,并缓缓加入0.7~1ml 40%~50%PEG4000作用1min,所述PEG4000的pH为8.5~9.0,然后缓慢加入无血清1640培养基15ml,以终止PEG的作用,37℃水浴5~10min,1000r/min离心10min弃上清,将细胞沉淀重悬于HAT选择培养基中,并以100μl~200μl/孔加入96孔培养板,置于37℃5%CO2培养箱中培养;培养7~10d后,以5μg~10μg/ml的纯化的病原体特异抗原包被96孔酶标板,以酶联免疫吸附试验检测杂交瘤的培养上清,挑取OD450≥0.5的强阳性细胞克隆,进行连续三次的有限稀释法克隆化,获得阳性杂交瘤细胞株,其染色体数为92~98,其分泌的单克隆抗体能够特异识别猪副嗜血杆菌,而不与其它毒素发生交叉反应,亲和力常数达109~10,轻链亚型为к或λ,重链亚型为IgG1、IgG2a、IgG2b或IgG3。
2.根据权利要求1所述的试纸条,其特征是检测印迹用抗猪副嗜血杆菌的配对单抗制备即用抗猪副嗜血杆菌的配对单抗溶液制备。
3.根据权利要求1所述的试纸条,其特征是支撑层用不吸水的硬质塑胶片条或硬纸条制成;测试端样品吸附纤维层用玻璃棉制成;金标抗体纤维层用玻璃棉和金标抗体制成,金标抗体是单抗或多克隆抗体。
4.根据权利要求1所述的试纸条,其特征是纤维素膜层用硝酸纤维素膜、或纯纤维素膜、或羧化纤维素膜制成。
5.根据权利要求1所述的试纸条,其特征是吸水材料层用吸水纸制成。
6.根据权利要求1所述的试纸条,其特征是检测印迹和对照印迹为直线式、或斜线式,纤维素膜层上含有一条检测印迹和一条对照印迹,检测印迹和对照印迹的排列形式为“||”、“//”、“\\”中的任一种。
7.根据权利要求1所述的试纸条,其特征是在测试端样品吸附纤维层、金标抗体纤维层及吸水材料层上覆盖有保护膜,在测试端样品吸附纤维层与金标抗体纤维层交界处对应的保护膜上印制有样品标记线,该标记线偏向测试端样品吸附纤维层一侧约0.5cm处。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310083786.3A CN103941001B (zh) | 2013-03-15 | 2013-03-15 | 猪副嗜血杆菌快速检测试纸条 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310083786.3A CN103941001B (zh) | 2013-03-15 | 2013-03-15 | 猪副嗜血杆菌快速检测试纸条 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103941001A CN103941001A (zh) | 2014-07-23 |
CN103941001B true CN103941001B (zh) | 2016-03-16 |
Family
ID=51188754
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310083786.3A Expired - Fee Related CN103941001B (zh) | 2013-03-15 | 2013-03-15 | 猪副嗜血杆菌快速检测试纸条 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103941001B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107402301A (zh) * | 2017-08-06 | 2017-11-28 | 潘金文 | 一种家禽病原体高通量检测芯片及其应用 |
CN109425738B (zh) * | 2017-09-01 | 2022-01-28 | 洛阳普泰生物技术有限公司 | 猪圆环病毒3型抗体检测试剂盒及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112995A1 (en) * | 2004-04-26 | 2005-12-01 | Choongang Vaccine Laboratory Co., Ltd. | Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
CN101339192A (zh) * | 2008-08-28 | 2009-01-07 | 河南省农业科学院 | 一步检测猪病毒性腹泻疾病病原的试纸条 |
CN102499982A (zh) * | 2011-12-21 | 2012-06-20 | 青岛易邦生物工程有限公司 | 副猪嗜血杆菌三价灭活疫苗的生产方法 |
CN102876635A (zh) * | 2012-09-28 | 2013-01-16 | 广东省农业科学院兽医研究所 | 抗副猪嗜血杆菌外膜蛋白omp5的单克隆抗体、杂交瘤细胞株及应用 |
-
2013
- 2013-03-15 CN CN201310083786.3A patent/CN103941001B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112995A1 (en) * | 2004-04-26 | 2005-12-01 | Choongang Vaccine Laboratory Co., Ltd. | Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof |
CN101339192A (zh) * | 2008-08-28 | 2009-01-07 | 河南省农业科学院 | 一步检测猪病毒性腹泻疾病病原的试纸条 |
CN102499982A (zh) * | 2011-12-21 | 2012-06-20 | 青岛易邦生物工程有限公司 | 副猪嗜血杆菌三价灭活疫苗的生产方法 |
CN102876635A (zh) * | 2012-09-28 | 2013-01-16 | 广东省农业科学院兽医研究所 | 抗副猪嗜血杆菌外膜蛋白omp5的单克隆抗体、杂交瘤细胞株及应用 |
Non-Patent Citations (2)
Title |
---|
副猪嗜血杆菌OMP5基因的克隆、表达及间接ELISA检测方法的建立;陈善真等;《中国农业科学》;19240315;第44卷(第14期);3036-3044页 * |
副猪嗜血杆菌的分离与单抗制备及其抗原表位鉴定;陈欣;《万方数据库》;20111031;摘要,第13-20、22页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103941001A (zh) | 2014-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101339192B (zh) | 一步检测猪病毒性腹泻疾病病原的试纸条 | |
CN104459144B (zh) | 一种猪伪狂犬病毒强毒株和疫苗毒株鉴别检测试纸 | |
CN104407137B (zh) | 一种猪瘟病毒强毒株和弱毒株鉴别检测试纸 | |
CN102818898A (zh) | 一步鉴别口蹄疫病毒感染和疫苗免疫动物的试纸条及其制备方法 | |
CN101344524B (zh) | 一步检测猪细小病毒、猪乙型脑炎病毒抗体的试纸条 | |
CN101339191A (zh) | 检测猪繁殖障碍性病毒传染病病原的试纸条 | |
CN103941001B (zh) | 猪副嗜血杆菌快速检测试纸条 | |
CN104459142A (zh) | 一种新城疫病毒强毒株和弱毒株鉴别检测试纸 | |
CN101358972B (zh) | 检测一种或多种猪病毒性腹泻疾病抗体的试纸条 | |
CN101339193B (zh) | 附红细胞体病快速诊断试纸条 | |
CN201285399Y (zh) | 检测猪繁殖障碍性病毒传染病病原的试纸条 | |
CN101424689B (zh) | 蓝舌病病毒检测试纸条 | |
CN103235127A (zh) | 马立克氏病病毒快速检测试纸条 | |
CN103940994B (zh) | 猪水疱病、猪水疱性疹及猪水疱性口炎三联检测试纸条 | |
CN204631047U (zh) | 快速检测番鸭细小病毒的试纸条 | |
CN103941014B (zh) | 猪气喘病、猪传染性胸膜肺炎及猪肺疫三联检测试纸条 | |
CN202814986U (zh) | 一步鉴别口蹄疫病毒感染和疫苗免疫动物的试纸条 | |
CN204495834U (zh) | 检测鸡喉气管炎病毒的试纸条 | |
CN204495838U (zh) | 一种检测禽呼肠孤病毒的试纸条 | |
CN102998443A (zh) | 尿液中尿酸检测免疫胶体金试纸条及制造方法 | |
CN103941013B (zh) | 猪胸膜肺炎放线杆菌内毒素快速检测试纸条 | |
CN103235129B (zh) | 马立克氏病病毒和j亚群禽白血病病毒快速联检试纸条 | |
CN103940991B (zh) | 猪沙门氏菌耐热毒素快速检测试纸条 | |
CN206573592U (zh) | 一种检测犬副流感病毒抗体的试纸条 | |
CN204495837U (zh) | 一种检测禽脑脊髓炎病毒的试纸条 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160316 |
|
CF01 | Termination of patent right due to non-payment of annual fee |